Kinross Gold Corporation vs Novartis AG — how do they compare? Kinross Gold Corporation trades at $27.5 (market cap $32.29B), while Novartis AG trades at $152.65 (market cap $295.37B). The key difference: Novartis AG is far larger — about 9.1× Kinross Gold Corporation's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| KGC | NVS | |
|---|---|---|
Market Cap | $32.29B | $295.37B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $168.62 |
52-Week Low | $18.70 | $119.31 |
Enterprise Value | $30.37B | $336.69B |
Dividend Yield | 0.59% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $27.59, up 0.69% with strong fundamental momentum. The company demonstrates robust earnings growth with three consecutive quarterly beats and impressive profitability metrics including 37.52% net margin and 36.95% ROE. Recent S&P upgrade to 'BBB' and positive project developments at Lobo-Marte support the bullish analyst consensus.
Outlook remains positive with 29 analysts showing 58.6% buy ratings and $37.20 consensus target, representing 35% upside. Key risks include gold price volatility and execution challenges at new projects. Strong free cash flow generation and disciplined capital allocation support continued shareholder returns.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →